

37. Malignant Pleural Mesothelioma

Authors

Valerie W. Rusch, Kari Chansky, Anna K. Nowak, David Rice, Hedy Kindler, Ritu R. Gill, William D. Travis, Harvey Pass

Emerging Prognostic Factors for Clinical Care

There are emerging data regarding the genomic profiles of MPM and the ways in which these correlate with histology and OS. However, none of this information is yet applicable to clinical care.

Risk Assessment Models

The AJCC recently established guidelines that will be used to evaluate published statistical prediction models for the purpose of granting endorsement for clinical use.¹ Although this is a monumental step toward the goal of precision medicine, this work was published only very recently. Therefore, the existing models that have been published or may be in clinical use have not yet been evaluated for this cancer site by the Precision Medicine Core of the AJCC. In the future, the statistical prediction models for this cancer site will be evaluated, and those that meet all AJCC criteria will be endorsed.

Recommendations for Clinical Trial Stratification

In addition to TNM and overall stage, the following parameters are recommended:

- Histologic type
- Sex
- Age
- Performance status
- Laboratory parameters including WBC, platelet count, and hemoglobin
- Surgical resection with curative intent (pleurectomy/decortications, extended pleurectomy/decortications or extrapleural pneumonectomy)
- For patients undergoing multimodality therapy, use of chemotherapy and/or radiotherapy

Bibliography

1. Kattan MW, Hess KR, Amin MB, et al. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. *CA: a cancer journal for clinicians*. 2016.